Partner With Us

As the only conference dedicated to GBM drug development, this is the go-to event for industry leaders to showcase themselves to an audience of experts from all areas of the glioblastoma landscape. As curiosity grows towards novel biomarkers and next-generation therapeutic modalities, this event is ideal for identifying gaps in the market that your services can fill.

As highlighted by the positive clinical readouts in glioma, the potential for a breakthrough in GBM treatment is growing. There has never been a better time to form crucial business partnerships   in what is looking to be a pivotal era of glioblastoma drug development.

Experts Need Your Help With:

22295_3rd_Glioblastoma_Drug_Development_Summit_logo_WO-removebg-preview

Discovering novel biomarkers for detecting treatment success and identifying responsive subgroups of patients

22295_3rd_Glioblastoma_Drug_Development_Summit_logo_WO-removebg-preview

Methods of improving patient stratification for enhanced clinical trial success

22295_3rd_Glioblastoma_Drug_Development_Summit_logo_WO-removebg-preview

GBM models which better replicate the complexity of the disease including spatiotemporal heterogeneity and the tumor microenvironment, to bridge the translatability gap to the clinic

22295_3rd_Glioblastoma_Drug_Development_Summit_logo_WO-removebg-preview

Overcoming the shortfalls of current imaging methods in accurately detecting tumor shrinkage and determining whether a treatment is working

22295_3rd_Glioblastoma_Drug_Development_Summit_logo_WO-removebg-preview

Improving diagnostics and accuracy of prognosis in order to better stratify GBM patients to better improve treatment outcomes

22295_3rd_Glioblastoma_Drug_Development_Summit_logo_WO-removebg-preview

The design of engineered cell therapies such as CAR-T cells which overcome barriers in GBM such as antigenic loss, protecting CAR-T from the tumor microenvironment and T cell exhaustion.

...and more!

Why Partner?

Community Icon
Solution Icon
Challenge Icon
Networking Icon

This summit brings together a dedicated community of pharma, biotech and academic KOLs sharing first-hand insight into the market need so that you can provide customized solutions

The GBM field face a unique set of challenges with a desperate need for solutions that makes them very receptive to solution providers like you for effective therapeutic delivery, informing patient stratification and measuring treatment success

A key challenge with GBM drug development is providing funders with reliable preclinical results, contingent on the use of suitable pre-clinical models; showcase the promise of your models to both funders and drug developers

Being the only glioblastoma-focused meeting, this is the go-to meeting for experts in the space providing you the ultimate networking experience with the key decision makers from all areas of glioblastoma research